Decisions of Herantis Pharma Plc’s Extraordinary General Meeting of shareholders
Herantis Pharma Plc (“Herantis”), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, announced on 11 November 2020 that it is evaluating alternatives to finance its Research & Development pipeline and subsequently convened an extraordinary general meeting to authorize the Board of Directors to resolve on potential share issues and certain other matters. The extraordinary general meeting was held in Helsinki on Wednesday, 2 December 2020. Shareholders participated in the meeting and exercised their rights only by voting in